Compare MTN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTN | QTTB |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 25.1M |
| IPO Year | 1997 | N/A |
| Metric | MTN | QTTB |
|---|---|---|
| Price | $161.76 | $2.94 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 4 |
| Target Price | ★ $176.50 | $7.33 |
| AVG Volume (30 Days) | 903.5K | ★ 9.0M |
| Earning Date | 12-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 7.24 | N/A |
| Revenue | ★ $2,975,101,000.00 | N/A |
| Revenue This Year | $2.69 | N/A |
| Revenue Next Year | $3.45 | N/A |
| P/E Ratio | $22.34 | ★ N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $129.85 | $1.35 |
| 52 Week High | $196.64 | $8.48 |
| Indicator | MTN | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 69.96 | 51.82 |
| Support Level | $140.00 | $3.06 |
| Resistance Level | $146.91 | $3.96 |
| Average True Range (ATR) | 4.35 | 0.51 |
| MACD | 2.37 | 0.03 |
| Stochastic Oscillator | 98.39 | 22.32 |
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.